Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence

Nathan Radakovich, BA, Luca Malcovati, MD, Manja Meggendorfer, PhD, Mikkael A. Sekeres, MD MS, Jacob Shreve, MD MS, Cameron Beau Hilton, MD, Yazan Rouphail, Wencke Walter, PhD, Stephan Hutter, PhD, Anna Gallì, Sarah Pozzi, Aaron T. Gerds, MDMS, Sudipto Mukherjee, MD PhD MPH, Cassandra M Kerr, MS, Babal K. Jha, PhD, Claudia Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Torsten Haferlach, MD, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140023

Published: 2020

Journal Articles

Personalized Transcriptomic Analyses Identify Unique Signatures That Correlate with Genomic Subtypes in Acute Myeloid Leukemia (AML) Using Explainable Artificial Intelligence

Yazan Rouphail, Nathan Radakovich, BA, Jacob Shreve, MD MS, Sudipto Mukherjee, MD PhD MPH, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-139522

Published: 2020

Journal Articles

Role of Oligoadenylate Synthetases in Myeloid Neoplasia

Metis Hasipek, PhD, Yihong Guan, PhD, Dale Grabowski, BS, Xiaorong Gu, PhD, Yogenthiran Saunthararajah, MD, Robert Silverman, PhD, George R Stark, PhD, Jaroslaw Maciejewski, PhD, Babal K. Jha, PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142457

Published: 2020

Journal Articles

Venetoclax Inhibition of Pyrimidine Synthesis Guides Methods for Integration with Decitabine or 5-Azacytidine That Are Non-Myelosuppressive

Xiaorong Gu, PhD, Rita Tohme, PhD, Mendel Goldfinger, MD, Benjamin K. Tomlinson, MD, Nneha Sakre, PhD, Shannon Hanmer, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Amit Verma, MBBS, Yogenthiran Saunthararajah, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-143200

Published: 2020

Journal Articles

Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms

Simona Pagliuca, MD, Yihong Guan, PhD, Anand D. Tiwari, PhD, Dale Grabowski, BS, Carmelo Gurnari, MD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, MD, Metis Hasipek, PhD, Laila Terkawi, Misam Zawit, MBBS, Hassan Awada, MD, Valeria Visconte, PhD, Yogenthiran Saunthararajah, MD, James G Phillips, PhD, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-143094

Published: 2020

Journal Articles

A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-139412

Published: 2020

Journal Articles

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Nathan Radakovich, BA, David A. Sallman, MD, Rena J. Buckstein, MD FRCPC, Andrew M. Brunner, MD, Sudipto Mukherjee, MD PhD MPH, Rami Komrokji, MD, Najla Al Ali, M.Sc, Jacob Shreve, MD MS, Yazan Rouphail, Cassandra M Kerr, MS, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-139815

Published: 2020

Journal Articles

TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity

Yihong Guan, PhD, Metis Hasipek, PhD, Bhumika J. Patel, MD, Dale Grabowski, BS, Anand D. Tiwari, PhD, Sunisa Kongkiatkamon, MD, Cassandra M Kerr, MS, Aziz Nazha, MD, Yogenthiran Saunthararajah, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-142875

Published: 2020

Journal Articles

Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Simona Pagliuca, MD, Carmelo Gurnari, MD, Diego Chowell, PhD, Chirag Krishna, Bhumika J. Patel, MD, Hassan Awada, MD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, MD, Ashwin Kishtagari, MBBS, Thomas Laframboise, PhD, Yogenthiran Saunthararajah, MD, Babal K. Jha, PhD, Valeria Visconte, PhD, Timothy Chan, MD PhD, Jaroslaw Maciejewski, PhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-142693

Published: 2020

Journal Articles

A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells By Targeting Protein Disulfide Isomerase

Metis Hasipek, PhD, Dale Grabowski, BS, Yihong Guan, PhD, Anand D. Tiwari, PhD, Xiaorong Gu, PhD, Jason Valent, MD, Jaroslaw Maciejewski, PhD, Frederic Joel Reu, James G Phillips, PhD, Babal K. Jha, PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-142847

Published: 2020

Journal Articles

Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion

Yihong Guan, PhD, Bhumika J. Patel, MD, Metis Hasipek, PhD, Dale Grabowski, BS, Hassan Awada, MD, Cassandra M Kerr, MS, Valeria Visconte, PhD, Aziz Nazha, MD, Yogenthiran Saunthararajah, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 453.

https://doi.org/10.1182/blood-2019-131525

Published: 2019

Journal Articles

Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Nathan Radakovich, BA, Mikkael A. Sekeres, MD MS, Cameron Beau Hilton, BA, Sudipto Mukherjee, MD PhD MPH, Jacob Shreve, MD MS, Yazan Rouphail, Rachel Shirley, Vera Adema, PhD, Hassan Awada, MD, Anjali S. Advani, MD, Cassandra M Kerr, MS, Yasunobu Nagata, MD PhD, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Aziz Nazha, MD

Blood (2019) 134 (Supplement_1): 2089.

https://doi.org/10.1182/blood-2019-126275

Published: 2019

Journal Articles

Reversible TET Inhibitor As a Hematopoietic Stem Cell Booster: A Novel Strategy to Improve Stem Cell Function

Blood (2019) 134 (Supplement_1): 2472.

https://doi.org/10.1182/blood-2019-129056

Published: 2019

Journal Articles

TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins

Blood (2019) 134 (Supplement_1): 1200.

https://doi.org/10.1182/blood-2019-132005

Published: 2019

Journal Articles

MPO as a Novel Susceptibility Gene in Myeloid Malignancies

Samuel Li, BA, Ruipeng Wei, Janet Wang, Undergraduate, Vera Adema, PhD, Teodora Kuzmanovic, BA, Bartlomiej P. Przychodzen, Yasunobu Nagata, MD PhD, Cassandra M Kerr, MS, Babal K. Jha, PhD, Francesc Sole, PhD, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Thomas Laframboise, PhD

Blood (2019) 134 (Supplement_1): 5402.

https://doi.org/10.1182/blood-2019-122127

Published: 2019

Journal Articles

Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms

Blood (2019) 134 (Supplement_1): 4238.

https://doi.org/10.1182/blood-2019-126967

Published: 2019

Journal Articles

Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia

Metis Hasipek, PhD, Yihong Guan, PhD, Dale Grabowski, BS, Jaroslaw P. Maciejewski, MD PhD, Hetty E. Carraway, MD MBA, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 2553.

https://doi.org/10.1182/blood-2019-130475

Published: 2019

Journal Articles

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

Yihong Guan, PhD, Anand D. Tiwari, PhD, James G Phillips, PhD, Metis Hasipek, PhD, Dale Grabowski, BS, Cassandra M Kerr, MS, Vera Adema, PhD, Yasunobu Nagata, MD PhD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Daniel Lindner, MD PhD, Manja Meggendorfer, PhD, Mohamed Abazeed, Mikkael A. Sekeres, MD MS, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 880.

https://doi.org/10.1182/blood-2019-131920

Published: 2019

Journal Articles

Clonal Architecture of TET2 Mutations Influences the Clinical Phenotype of Patients with Myeloid Neoplasms

Cassandra M. Hirsch, BS, Aziz Nazha, MD, Kneen Kassy, Manja Meggendorfer, PhD, Bartlomiej P. Przychodzen, MSc, Niroshan Nadarajah, Vera Adema, PhD, Yasunobu Nagata, MD PhD, Valeria Visconte, PhD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Ryszard Ólinski, Professor, Sudipto Mukherjee, MD PhD MPH, Babal K Jha, PhD, Thomas Laframboise, PhD, Tomas Radivoyevitch, PhD, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 4228.

https://doi.org/10.1182/blood.V130.Suppl_1.4228.4228

Published: 2017

Journal Articles

Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)

Yazan F. Madanat, MD, Mikkael A. Sekeres, MD MS, Karam Al-Issa, MD, Cassandra M. Hirsch, BS, Sudipto Mukherjee, MD PhD MPH, Aaron T. Gerds, MDMS, Nour Abuhadra, MD, Babal K Jha, PhD, Vera Adema, PhD, Anjali S. Advani, MD, Yasunobu Nagata, MD PhD, Teodora Kuzmanovic, BA, Bartlomiej P. Przychodzen, MSc, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Aziz Nazha, MD

Blood (2017) 130 (Supplement 1): 4245.

https://doi.org/10.1182/blood.V130.Suppl_1.4245.4245

Published: 2017

NARROW

Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence

Personalized Transcriptomic Analyses Identify Unique Signatures That Correlate with Genomic Subtypes in Acute Myeloid Leukemia (AML) Using Explainable Artificial Intelligence

Role of Oligoadenylate Synthetases in Myeloid Neoplasia

Venetoclax Inhibition of Pyrimidine Synthesis Guides Methods for Integration with Decitabine or 5-Azacytidine That Are Non-Myelosuppressive

Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms

A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity

Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells By Targeting Protein Disulfide Isomerase

Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion

Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Reversible TET Inhibitor As a Hematopoietic Stem Cell Booster: A Novel Strategy to Improve Stem Cell Function

TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins

MPO as a Novel Susceptibility Gene in Myeloid Malignancies

Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms

Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

Clonal Architecture of TET2 Mutations Influences the Clinical Phenotype of Patients with Myeloid Neoplasms

Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only